01 / ATLAS

What it is

BPC-157 is a 15-amino-acid peptide studied mainly in experimental tissue research. [1]

02 / ATLAS

How it works

Studies have investigated tendon fibroblast migration and survival, including FAK–paxillin signaling. These mechanisms were observed in experimental models. [1]

03 / ATLAS

What research shows

Preclinical research suggests effects on some repair processes. A cellular response in a laboratory does not demonstrate healing of a tendon tear in humans. [1]

04 / ATLAS

Study data

Chang et al., 2011: tests on rat tendon cells and tissue fragments examined cell migration and survival under stress. This was not a randomized therapeutic trial in patients. [1]

The study does not provide a validated clinical regimen for human use.

05 / ATLAS

Safety and observed adverse reactions

The FDA describes insufficient safety information and potential issues involving immunogenicity, impurities and substance characterization. [2]

These sources cannot establish the true frequency of adverse reactions during unsupervised use.

06 / ATLAS

Research status

Evidence for indications promoted online remains insufficient for robust therapeutic conclusions. Evaluation of a substance for compounding is not equivalent to medicine approval. [3]

07 / REFERENCES

Studies and sources

  1. Chang et al. · Tendons, cell migration and BPC-157 (2011) ↗Original research · preclinical
  2. FDA · Potential risks and safety-data gaps ↗Official assessment · United States
  3. FDA · BPC-157 documentation, 2026 ↗Official document · PDF
Back to the atlasFurther information / Contact